A dense regulatory day defines the health and biotech tape, with GSK And AstraZeneca (LSE:AZN) each securing meaningful FDA milestones while Hemogenyx Pharmaceuticals (LSE:HEMO) pays the familiar post-fundraise price. Other names are moving sharply in both directions, with AOTI surging and Genflow building on positive gene therapy data.
GSK clears FDA hurdle on hepatitis B drug
GSK (LSE:GSK) advances +0.45% to 2025.0p after the FDA accepted its New Drug Application for bepirovirsen for chronic hepatitis B, granting both Priority Review and Breakthrough Therapy Designation. The agency has set a PDUFA date of 26 October, giving GSK a clear regulatory timeline for what would be a significant addition to its infectious disease franchise.
AstraZeneca lands first triple-therapy asthma approval
AstraZeneca (LSE:AZN) edged -0.44% to 13910.0p despite a landmark US clearance: the FDA has approved Breztri Aerosphere, as the first and only single-inhaler fixed-dose triple therapy for maintenance treatment of asthma in patients aged 12 and older. The approval extends Breztri's existing COPD indication into asthma, broadening the addressable patient population for one of AstraZeneca's core respiratory assets.
Hemogenyx drops as £3m placing hits the tape
Hemogenyx Pharmaceuticals (LSE:HEMO) falls -13.35% to 695.8p after raising £3m through a direct institutional subscription. The proceeds are earmarked to accelerate its Phase I programme for HG-CT-1 and to establish local manufacturing capability ahead of early commercial access. Dilution pressure is the immediate market reaction, though the funding secures the next clinical milestone.
Genflow rises as tier-1 animal health talks widen
Genflow Biosciences (LSE:GENF) climbs +12.0% To 2.8p after signing additional confidentiality agreements with Tier-1 animal health companies to extend third-party review of data from its canine SIRT6-centred gene therapy programme. The move follows positive preliminary interim results and signals that commercial interest in the platform is broadening beyond initial contacts.
AOTI surges; One Health steady in mixed small-cap session
AOTI (LSE:AOTI) is the standout mover in the health small-cap space, jumping +27.06% To 54.0p. One Health Group (LSE:OHGR) trades more quietly, adding +1.0% to 252.0p. The contrast underscores a bifurcated tape in which catalyst-driven names attract sharp re-ratings while operationally stable businesses hold their ground without fanfare.
PureTech and Ondine make measured gains
PureTech Health (LSE:PRTC) edged +0.8% To 126.2p, while Ondine Biomedical (LSE:OBI) added +4.0% To 13.0p. Both names move in positive territory without a single dominant catalyst in today's newsflow, reflecting a broader constructive tone across the sector's mid- and micro-cap tier.
